Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer

This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to provide a more accurate evidence for clinical diagnosis, promote the development of individualized treatment for gastric cancer, and ultimately improve the prognosis of patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Gastric Cancer Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yunnan Cancer Hospital

Kunming, Yunnan, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(a)Patients with gastric adenocarcinoma confirmed by histopathological biopsy and definite microsatellite status determined by immunohistochemistry (IHC);
(b)Abdominal dual-phase Quark CT scanning was performed within 2 weeks before surgery;
(c)aged ≥ 18 years old

Exclusion criteria

(a)Combined with other primary tumors;
(b) The image quality does not meet the diagnostic criteria;
(c)Those who cannot tolerate CT examination.

Treatment and study plan

o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses

Diagnostic Test

Abdominal CT scans were performed in addition to conventional treatment regimens

Primary outcomes

Pathological N stage

Time frame: 1 day

The lymph node status confirmed by surgical pathology was used as the reference standard

Sponsors and collaborators

Lead sponsor

Yunnan Cancer Hospital

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: May 4, 2026
Registry last updated: May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting